Valuation: Inventiva

Market Cap 79Cr 89Cr 73Cr 66Cr 125.76Cr 8.3TCr 129.27Cr 876.05Cr 349.04Cr 4.45TCr 332.23Cr 325.18Cr 14TCr P/E 2026 *
-4.89x
P/E 2027 * -7.15x
Enterprise Value 66Cr 73Cr 61Cr 55Cr 104.09Cr 6.87TCr 106.99Cr 725.1Cr 288.9Cr 3.68TCr 274.98Cr 269.15Cr 12TCr EV / Sales 2026 *
128x
EV / Sales 2027 * 162x
Free-Float
85.61%
Yield 2026 *
-
Yield 2027 * -
1 day+0.90%
1 week-5.35%
Current month+5.66%
1 month+17.48%
3 months-19.04%
6 months-26.15%
Current year-14.83%
1 week 3.18
Extreme 3.18
3.74
1 month 2.57
Extreme 2.57
3.76
Current year 2.57
Extreme 2.57
6.2
1 year 2.57
Extreme 2.57
6.2
3 years 1.43
Extreme 1.434
6.2
5 years 1.43
Extreme 1.434
12.7
10 years 1.43
Extreme 1.434
16.3
Manager TitleAgeSince
Chief Executive Officer 53 01/10/2025
Director of Finance/CFO 59 22/04/2026
Chief Operating Officer - 31/08/2026
Director TitleAgeSince
Director/Board Member 76 01/02/2017
Director/Board Member 63 27/05/2019
Director/Board Member 52 01/05/2024
Date Insider Type Main position Quantity % Market Cap. Importance
10/01/26 Others

Executive/Senior Manager

50,000 0.0262%
10/01/26 Others

General Counsel

25,000 0.0131%
10/01/26 Others

Head of Human Resources

25,000 0.0131%
Change 5-day change 1-year change 3-year change Capi.($)
+0.90%-5.35%+1.97%-1.90% 89Cr
+0.01%+11.10%+60.83%+70.43% 6.83TCr
+1.22%+9.56%+15.97%+90.23% 6.03TCr
+0.24%+1.35%+23.78%+97.55% 5.59TCr
+1.60%+19.44%+28.80%+112.95% 4.84TCr
-1.32%+4.78%+29.15%+40.40% 4.53TCr
-3.54%-0.60%+207.76%+879.50% 4.18TCr
-3.33%+6.90%+22.78%+48.07% 3.45TCr
-2.19%-3.71%+90.94%+66.33% 3.38TCr
-1.77%+0.83%+46.57%-0.16% 2.6TCr
Average -0.82%+4.32%+52.86%+140.34% 4TCr
Weighted average by Cap. -0.67%+5.23%+55.19%+153.26%

Financials

2026 *2027 *
Net sales 51.32L 57.23L 47.3L 42.95L 81.29L 54Cr 83.56L 5.66Cr 2.26Cr 29Cr 2.15Cr 2.1Cr 91Cr 22.39L 24.96L 20.63L 18.74L 35.46L 23Cr 36.45L 2.47Cr 98.43L 13Cr 93.69L 91.7L 40Cr
Net income -16Cr -18Cr -15Cr -13Cr -25Cr -1.67TCr -26Cr -175.95Cr -70Cr -893.14Cr -67Cr -65Cr -2.82TCr -21Cr -23Cr -19Cr -18Cr -33Cr -2.19TCr -34Cr -230.97Cr -92Cr -1.17TCr -88Cr -86Cr -3.71TCr
Net Debt -14Cr -15Cr -13Cr -11Cr -22Cr -1.43TCr -22Cr -150.95Cr -60Cr -766.25Cr -57Cr -56Cr -2.42TCr -43Cr -48Cr -40Cr -36Cr -68Cr -4.52TCr -70Cr -477.01Cr -190.05Cr -2.42TCr -180.9Cr -177.06Cr -7.65TCr
Projected Income Statement - Annual - Inventiva
Logo Inventiva
Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH and other diseases with significant unmet medical need. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease. Inventiva owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly owned research and development facility.
Employees
87
Date Price Change Volume
10/26/10 €3.360 +0.90% 4,80,123
09/26/09 €3.330 -2.06% 4,91,155
06/26/06 €3.400 +1.19% 6,96,697
05/26/05 €3.360 -5.22% 6,43,784
04/26/04 €3.545 -0.14% 10,06,801
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
MarketScreener Ratings - Inventiva
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
3.360EUR
Average target price
9.770EUR
Spread / Average Target
+190.77%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Inventiva